Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial.
dc.contributor.author | Christodoulou, Marianna | |
dc.contributor.author | Blackhall, Fiona H | |
dc.contributor.author | Mistry, Hitesh | |
dc.contributor.author | Leylek, A | |
dc.contributor.author | Knegjens, J | |
dc.contributor.author | Remouchamps, V | |
dc.contributor.author | Martel-Lafay, I | |
dc.contributor.author | Farre, N | |
dc.contributor.author | Zwitter, M | |
dc.contributor.author | Lerouge, D | |
dc.contributor.author | Pourel, N | |
dc.contributor.author | Janicot, H | |
dc.contributor.author | Scherpereel, A | |
dc.contributor.author | Tissing-Tan, C | |
dc.contributor.author | Peignaux, K | |
dc.contributor.author | Geets, X | |
dc.contributor.author | Konopa, K | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.date.accessioned | 2018-12-10T11:48:52Z | |
dc.date.available | 2018-12-10T11:48:52Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, et al.Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2018 Oct 31 | en |
dc.identifier.pmid | 30391573 | en |
dc.identifier.doi | /10.1016/j.jtho.2018.09.027 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621395 | |
dc.description.abstract | INTRODUCTION: There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC. METHODS: We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice-daily fractions/19 days or 66 Gy/33 once-daily fractions/45 days concurrently with platinum-based chemotherapy. Overall survival and progression-free survival were evaluated using Kaplan-Meier methodology and Cox proportional hazards regression. RESULTS: Of 547 patients randomized between April 2008 and November 2013, 57 did not receive protocol treatment and were excluded. Of the 490 patients included, 67 (14%) were 70 years of age or older (median age: 73 years; range: 70-82). Fewer older patients received the optimal number of radiotherapy fractions (73% versus 85%; p = 0.03); however, chemotherapy compliance was similar in both groups (p = 0.24). Neutropenia grade 3/4 occurred more frequently in the elderly (84% versus 70%; p = 0.02) but rates of neutropenic sepsis (4% versus 7%; p = 0.07) and death (3% versus 1.4%; p = 0.67) were similar in both groups. With a median follow-up of 46 months; median survival in the elderly versus younger groups was 29 (95% confidence interval [CI]: 21-39) versus 30 months (95% CI: 26-35), respectively; (hazard ratio: 1.15, 95% CI: 0.84-1.59; p = 0.38). Median time to progression in the elderly versus younger groups was 18 months (95% CI: 13-31) versus 16 months (95% CI: 14-19), respectively (hazard ratio: 1.04, 95% CI: 0.76-1.41; p = 0.81). CONCLUSIONS: Concurrent chemoradiotherapy with modern radiotherapy techniques should be a treatment option for fit, older patients." | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org//10.1016/j.jtho.2018.09.027 | en |
dc.title | Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. | en |
dc.type | Article | en |
dc.contributor.department | Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester | en |
dc.identifier.journal | Journal of Thoracic Oncology | en |